1
|
Wu CY, Budha N, Gao Y, Castro H, Nkobena A, Ben Y, Sahasranaman S. Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Wu CY, Tang T, Liu L, Ben Y, Sahasranaman S, Gao Y. Population pharmacokinetics of tislelizumab in patients with advanced tumors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Sohn J, Sharma P, Dirix L, Allison J, Ben Y, Kataria R, Ferro S, Asubonteng K, Oh DY. Abstract P1-08-03: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-08-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J Sohn
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - P Sharma
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - L Dirix
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - J Allison
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - Y Ben
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - R Kataria
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - S Ferro
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - K Asubonteng
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| | - D-Y Oh
- Yonsei University Severance Hospital, Seoul, Korea; The University of Texas MD Anderson Cancer Center, Houston, TX; AZ Sint Augustinus, Antwerp, Belgium; AstraZeneca, Gaithersburg, MD; Seoul National University Hospital, Seoul, Korea
| |
Collapse
|
4
|
Zheng Y, Jin X, Narwal R, Jin CYD, Gupta A, Ben Y, Mukhopadhyay P, Higgs B, Roskos L. Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Zajac M, Boothman AM, Ben Y, Gupta A, Antal J, Jin X, Nielsen A, Manriquez G, Barker C, Wang P, Patil P, Schechter N, Rebelatto M, Walker J. Abstract 664: Analytical validation and clinical utility of an immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial carcinoma patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A high quality programmed cell death ligand-1 (PD-L1) diagnostic may help to identify patients (pts) most likely to respond to anti-PD-L1/programmed cell death-1 (PD-1) therapy. Here we describe a PD-L1 immunohistochemical (IHC) diagnostic test developed for urothelial carcinoma (UC) pts treated with durvalumab.
Methods: The IHC assay uses an anti-human PD-L1 rabbit mAb optimized for detection of both tumor cell (TC) and tumor-associated immune cell (IC) PD-L1 expression with the OptiView DAB IHC Detection Kit on the automated VENTANA BenchMark ULTRA platform. The assay was validated for intended use in UC formalin-fixed, paraffin-embedded samples in a series of studies that addressed sensitivity, specificity, robustness and precision and implemented in Study CD-ON-MEDI4736-1108 (NCT01693562). Pts were evaluated using the VENTANA PD-L1 (SP263) Assay at a prespecified PD-L1 expression cut-off. Efficacy was analyzed in pts with PD-L1 low/negative (defined as TC <25% and IC <25%) UC and in pts with PD-L1 high (defined as TC ≥25% or IC ≥25%) UC.
Results: The VENTANA PD-L1 (SP263) Assay met all the predefined acceptance criteria (average positive agreement and average negative agreement >85%), showing analytical specificity, sensitivity and precision. It demonstrated ≥97% and ≥85% inter-reader precision agreement for TC and IC respectively. For intra-reader precision, it demonstrated >96% and >87% agreement for TC and IC respectively. For intra-day performance, the assay demonstrated ≥96% agreement for TC and IC and for inter-day performance, it demonstrated ≥98% and 100% agreement for TC and IC respectively. Precision studies for inter-antibody lot, inter-detection kit lot and intra-platform demonstrated >97% agreement for both TC and IC. Inter-laboratory testing was performed at 3 external laboratories and demonstrated an overall agreement rate of 92.3%. The VENTANA PD-L1 (SP263) Assay was implemented in Study CD-ON-MEDI4736-1108 and durvalumab demonstrated clinical activity and durability of response in both PD-L1 high and PD-L1 low/negative subgroups, yet with different response rates. In addition, given the high negative predictive value of the assay, it is especially helpful in evaluating the likelihood of response to durvalumab; pts who were classified as PD-L1 high with the VENTANA PD-L1 (SP263) Assay tended to have a higher objective response rate per RECIST v1.1 than pts who were PD-L1 low/negative.
Conclusions: These data show that determination of PD-L1 expression in TC and IC in UC pts using the VENTANA PD-L1 (SP263) Assay is precise and highly reproducible and highlight the utility of the assay in a clinical setting. The VENTANA SP263 Assay is especially helpful in informing pts and physicians on the likelihood of response to durvalumab, but not for the purpose of restricting treatment to only PD-L1 high pts.
Citation Format: M Zajac, A M. Boothman, Y Ben, A Gupta, J Antal, X Jin, A Nielsen, G Manriquez, C Barker, P Wang, P Patil, N Schechter, M Rebelatto, J Walker. Analytical validation and clinical utility of an immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial carcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 664. doi:10.1158/1538-7445.AM2017-664
Collapse
Affiliation(s)
- M Zajac
- 1AstraZeneca, Cambridge, United Kingdom
| | | | - Y Ben
- 2AstraZeneca, Gaithersburg, MD
| | - A Gupta
- 3MedImmune, Gaithersburg, MD
| | - J Antal
- 3MedImmune, Gaithersburg, MD
| | - X Jin
- 3MedImmune, Gaithersburg, MD
| | - A Nielsen
- 4Ventana Medical Systems Inc., Tucson, AZ
| | | | - C Barker
- 1AstraZeneca, Cambridge, United Kingdom
| | - P Wang
- 4Ventana Medical Systems Inc., Tucson, AZ
| | - P Patil
- 4Ventana Medical Systems Inc., Tucson, AZ
| | | | | | - J Walker
- 1AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
6
|
Zajac M, Boothman AM, Ben Y, Gupta A, Jin X, Antal J, Sharpe A, Scott M, Rebelatto M, Walker J. Abstract 656: PD-L1 expression in primary lesions vs metastatic sites and by demographics in advanced urothelial carcinoma samples. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Determination of programmed cell death ligand-1 (PD-L1) expression levels in tumors may help physicians understand which patients (pts) are most likely to respond to anti-PD-1/PD-L1 therapies in urothelial carcinoma (UC). Understanding the impact of different sample types and demographics on PD-L1 expression is important to determine suitability of tumor biopsies for testing.
Methods: As of July 24, 2016, 363 pts screened in the UC cohort of Study CD-ON-MEDI4736-1108 (NCT01693562) had tissue available for analysis and 47 pts had provided paired primary and metastatic samples. FFPE samples were tested in a central laboratory with the VENTANA PD-L1 (SP263) Assay using a BenchMark ULTRA instrument. Pts were classified as having either PD-L1 high (PD-L1 expression ≥25% either on tumour cells [TC] or immune cells [IC]) or PD-L1 low/negative (<25% on TC and IC) tumors. PD-L1 high prevalence was reported in primary vs metastatic sites, and by age, sex and race.
Results: PD-L1 status was evaluable for 332/363 (91.5%) pts (175/332 [52.7%] PD-L1 high and 157/332 [47.3%] PD-L1 low/negative) whose UC specimens were tested (intent to diagnose [ITD] population). Overall percentage agreement between paired primary and metastatic samples, based on combined TC/IC scoring ≥25%, was 74.5% (95% CI 59.7 - 86.1%). In the ITD population, using only the samples from which patient PD-L1 expression status was determined, PD-L1 high prevalence in primary and metastatic samples was 57.1% and 50.9% respectively (p=0.343, not significant). The proportion of pts with PD-L1 high status was not enriched in any demographic group (Table).
Conclusions: Initial data from UC pts in Study 1108 showed similar PD-L1 high prevalence in primary and metastatic lesions and good concordance between paired primary and metastatic samples. These results build optimism that samples obtained from either location could be used to determine PD-L1 status. Further data are needed to confirm these findings.
Patients screened for UC cohort with evaluable PD-L1 result - ITD population (n = 332)ParameterPD-L1 high, n (%)P valueAge, years<65 (n=131)73 (55.7%)0.438≥65 (n=201)102 (50.8%)SexMale (n=236)127 (53.8%)0.610Female (n=96)48 (50.0%)RaceAsian (n=52)23 (44.2%)Asian vs White: 0.406Black or African American (n=10)6 (60.0%)White (n=218)113 (51.8%)Other (n=9)4 (44.4%)
Citation Format: M Zajac, A M. Boothman, Y Ben, A Gupta, X Jin, J Antal, A Sharpe, M Scott, M Rebelatto, J Walker. PD-L1 expression in primary lesions vs metastatic sites and by demographics in advanced urothelial carcinoma samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 656. doi:10.1158/1538-7445.AM2017-656
Collapse
Affiliation(s)
- M Zajac
- 1AstraZeneca, Cambridge, United Kingdom
| | | | - Y Ben
- 2AstraZeneca, Gaithersburg, MD
| | - A Gupta
- 3MedImmune, Gaithersburg, MD
| | - X Jin
- 3MedImmune, Gaithersburg, MD
| | - J Antal
- 3MedImmune, Gaithersburg, MD
| | - A Sharpe
- 1AstraZeneca, Cambridge, United Kingdom
| | - M Scott
- 1AstraZeneca, Cambridge, United Kingdom
| | | | - J Walker
- 1AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
7
|
Park S, Castellano D, Petrylak D, Galsky M, van der Heijden M, Loriot Y, Ogawa O, Su WP, Huang W, Levin W, Ferro S, Ben Y, Bellmunt J, Powles T. 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw583.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
He X, Mao Y, Ben Y, Ma C, Zhang Z. Clinical characteristics and basic research development of Peutz-Jeghers syndrome. Chin Med Sci J 2001; 16:49-51. [PMID: 12899349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
OBJECTIVE To improve clinical knowledge of Peutz-Jeghers syndrome. METHODS Eight patients with Peutz-Jeghers syndrome from 1984 to 1998 in our hospital were retrospectively reviewed and analyzed in the present study. RESULT The result of this analysis showed that there were 4 patients appeared with family histories of Peutz-Jeghers syndrome. All of the included patients admitted to the hospital with various complications, and eventually received surgical interventions for these complications, among which, 6 of them had intestinal obstructions mostly (5/6) due to small bowel intussusception, and 2 of them suffered with hemafecia. Post-operative recoveries were generally satisfactory with zero mortality. CONCLUSION Peutz-Jeghers syndrome is an uncommon digestive dominant hereditary disease. The diagnosis of it with history, symptoms, signs, and proper examinations usually is not difficult Surgical interventions are necessary once complications occur.
Collapse
Affiliation(s)
- X He
- Department of Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730
| | | | | | | | | |
Collapse
|
9
|
Ben Y, Yu H, Wang Z, Miao Q, Ren H, Zhang Z, Li Z. Adenosquamous lung carcinoma: clinical characteristics, surgical treament and prognosis. Chin Med Sci J 2000; 15:238-40. [PMID: 12906147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
OBJECTIVE The effectiveness of surgical resection of adenosquamous carcinoma of the lung remains poorly defined because of the histology's relatively low frequency, the failure in most published series to separate adenosquamous carcinoma from the other variants of non-small cell lung carcinoma. To define the effectiveness of treatment of adenosquamous carcinoma, we have retrospectively reviewed our hospital experience over a 12-year period. METHODS Retrospectively reviewed 22 cases of adenosquamous carcinoma who were surgically treated, except one patient, in the PUMCH from Jan. 1985 to Aug. 1997. This series constitutes the 1.9% of a total of 1 245 patients with all types of surgical treatment for the primary lung cancer during the same time. RESULTS The adenosquanous carcinoma was mostly presented in the old patients with a mean age of 60 years and mostly located in the peripheral of lung (n = 20). The overall 5-year survival was 23%. Those with stage I tumors survival was only 18% (n = 13), stage II 5%. The survival in stage III tumos was not longer than 25 months and in stage IV survival was not longer than 12 months. CONCLUSION Our results suggest that adenosquamous carcinoma of lung was a virulent tumor, which exhibited highly aggressive biological behavior with early lymph nodes metastasis (46%) and its prognosis was worse than that of both squamous cell carcinoma and adenocarcinoma.
Collapse
Affiliation(s)
- Y Ben
- Department of Cardiothoracic Surgery, PUMC Hospital, CAMS & PUMC, Beijing 100730
| | | | | | | | | | | | | |
Collapse
|
10
|
Yu B, Zhou G, Wang B, Ben Y, Yan H, Shao Y, Wang B. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis. Chin Med Sci J 1991; 6:166-8. [PMID: 1838936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Ciclopirox olamine, a new synthetic substituted pyridone derivative, is an antimycotic agent with activity against a broad spectrum of pathogenic and nonpathogenic fungi. The clinical efficacy and safety of 8% ciclopirox olamine nail liquor were evaluated in 100 cases with finger (or great toe) onychomycosis. After 16 weeks and 24 weeks of treatment for finger and great toe onychomycosis, respectively, the overall therapeutic results were excellent in 36 cases, good in 17, fair in 24, and poor in 23. The period of treatment was extended in 31 cases; among them, 10 cases showed further improvement. As for in vitro inhibitory activity, the MIC of ciclopirox olamine against T. rubrum and C. albicans was 1 to 4 mg/L and 1 to 16 mg/L, respectively. This study indicates that 8% ciclopirox olamine nail liquor, with its satisfactory efficacy and lack of side effects, is a good remedy for onychomycosis.
Collapse
Affiliation(s)
- B Yu
- PUMC Hospital, CAMS, Beijing
| | | | | | | | | | | | | |
Collapse
|
11
|
Rhee H, Koyamada K, Ishikawa S, Kakihata H, Ben Y. [Surgical treatment of idiopathic hypertrophic subaortic stenosis]. Kyobu Geka 1973; 26:132-41. [PMID: 4734922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|